Compare KIO & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KIO | KMDA |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | Israel |
| Employees | 2400 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.6M | 385.3M |
| IPO Year | N/A | N/A |
| Metric | KIO | KMDA |
|---|---|---|
| Price | $11.56 | $7.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 136.5K | 101.6K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 10.82% | 2.84% |
| EPS Growth | N/A | ★ 30.41 |
| EPS | N/A | ★ 0.35 |
| Revenue | N/A | ★ $174,787,000.00 |
| Revenue This Year | N/A | $14.90 |
| Revenue Next Year | N/A | $9.91 |
| P/E Ratio | ★ N/A | $19.76 |
| Revenue Growth | N/A | ★ 10.36 |
| 52 Week Low | $10.52 | $5.54 |
| 52 Week High | $13.59 | $9.16 |
| Indicator | KIO | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 54.22 |
| Support Level | $11.67 | $6.63 |
| Resistance Level | $11.65 | $7.07 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 39.29 | 65.83 |
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.